UNASSIGNED: This study systematically compared the role of m6A regulators of ESCC and EAC in terms of molecular characteristics, immuno-oncology characteristics, and clinical relevance, and validated our findings in a long-term follow-up patient cohort.
UNASSIGNED: There were many differences in m6A regulators between ESCC and EAC in terms of expression patterns, genetic variation, association with tumor pathways, immune signatures, and immunotherapy sensitivity. Furthermore, VIRMA was identified as a factor with opposite functional and prognostic effects in ESCC and EAC. ESCC patients with high VIRMA expression and EAC patients with low VIRMA expression had a better prognosis. Single-center data showed that low expression of FTO may be associated with superior immunotherapy efficacy in ESCC patients.
UNASSIGNED: The results herein provide novel ideas for understanding the tumor characteristics, occurrence, and development of ESCC and EAC, and suggest new targets for the treatment and intervention of EC.
UNASSIGNED:本研究系统地比较了ESCC和EAC的m6A调节剂在分子特征方面的作用,免疫肿瘤学特征,和临床相关性,并在长期随访患者队列中验证了我们的发现。
UNASSIGNED:在表达模式方面,ESCC和EAC之间的m6A调节因子存在许多差异,遗传变异,与肿瘤通路相关,免疫特征,和免疫疗法的敏感性。此外,VIRMA被确定为在ESCC和EAC中具有相反的功能和预后影响的因素。VIRMA高表达的ESCC患者和VIRMA低表达的EAC患者预后较好。单中心数据显示,在ESCC患者中,FTO的低表达可能与较好的免疫治疗效果相关。
UASSIGNED:本文的结果为理解肿瘤特征提供了新的思路,发生,以及ESCC和EAC的发展,并提出新的治疗和干预措施的目标。